Targets › ERGOSTEROL
3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 4; Infectious disease, Oncology, Other; next expected readout Jun 2027.
Open in Phaseline: the race on ERGOSTEROL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Copenhagen University Hospital, Rigshospitalet | Fluconazole Cytochrome P450 51 inhibitor | ERGOSTEROL | Phase 4 | Cystectomy | Jun 2027 |
| National Cancer Institute (NCI) | Itraconazole Cytochrome P450 51 inhibitor | ERGOSTEROL | Phase 2 | Barrett Esophagus | Aug 2030 |
| AVVA Pharmaceuticals | Clotrimazole Cytochrome P450 51 inhibitor | ERGOSTEROL | Phase 2 | Candidal Vulvovaginitis (ICD-10 Code: B37.3) | – |
Candidal Vulvovaginitis (ICD-10 Code: B37.3) (1) Barrett Esophagus (1) Cystectomy (1)
small molecule (3)
AVVA Pharmaceuticals (1) National Cancer Institute (NCI) (1) Copenhagen University Hospital, Rigshospitalet (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.